Posts Tagged ‘DNDN’
Prostate Cancer Drug Improves Survival
Dendreon said its prostate cancer treatment Provenge prolonged patient survival, providing fuel for a rally in its shares.
Duration : 0:4:51
Posted in Prostate Cancer Treatment | 
Tags: cancer, Dendreon, DNDN, FDA, prostate, Provenge, treatment | 
4 Comments »
Treating Cancer – Dendreon’s Provenge May Improve Survival Rate for Prostate Cancer
Dendreon Corporation (NASDAQ:
DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE®
(sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of
significantly improving overall survival compared to placebo. The data were presented at
the American Urological Association (AUA) Annual Meeting.
Duration : 0:3:14
Posted in Prostate Cancer Survival Rate |
Tags: cancer, Cancer Study, Cancer Treatment, Dendreon, DNDN, prostate, Prostate Cancer, Provenge, Treat Cancer |
1 Comment »
Treating Cancer – Dendreon’s Provenge May Improve Survival Rate for Prostate Cancer
Dendreon Corporation (NASDAQ:
DNDN) today announced that its pivotal Phase 3 IMPACT study of PROVENGE®
(sipuleucel-T) in men with advanced prostate cancer met its primary endpoint of
significantly improving overall survival compared to placebo. The data were presented at
the American Urological Association (AUA) Annual Meeting.
Duration : 0:3:14
Posted in Prostate Cancer Prognosis |
Tags: cancer, Cancer Study, Cancer Treatment, Dendreon, DNDN, prostate, Prostate Cancer, Provenge, Treat Cancer |
1 Comment »